EyePoint (EYPT) EBIT (2010 - 2026)
EyePoint (EYPT) posted EBIT of -$87.2 million for Q1 2026, down 24.0% sequentially from -$70.3 million in Q4 2025, and down 78.61% YoY from -$407.7 million in Q1 2025.
Analysis
EyePoint (EYPT) EBIT (2010 - 2026) Analysis & Trends
EyePoint has reported EBIT for 17 years, with the latest figure at -$87.2 million in Q1 2026.
- Quarterly EBIT fell 78.61% year-over-year to -$87.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$281.8 million (down 74.64% YoY) and the FY2025 annual result came in at -$243.4 million, down 66.9% from the prior year.
- EBIT slipped to -$87.2 million in Q1 2026 per EYPT's latest filing, from -$70.3 million in the prior quarter.
- Over five years, EBIT peaked at -$14.4 million in Q3 2023 and troughed at -$87.2 million in Q1 2026.
- A 5-year average of -$38.3 million and a median of -$33.3 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2024: EBIT jumped 62.61% in 2023, then slumped 176.62% in 2024.
- Over 5 years, EBIT stood at -$43.7 million in 2022, then surged by 62.61% to -$16.4 million in 2023, then tumbled by 176.62% to -$45.2 million in 2024, then sank by 55.5% to -$70.3 million in 2025, then declined by 24.0% to -$87.2 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$87.2 million, -$70.3 million, and -$62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -97.38 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -97.38 Mn |
| Mar 31, 2026 | -87.23 Mn |
| Dec 31, 2025 | -70.35 Mn |
| Sep 30, 2025 | -62.03 Mn |
| Jun 30, 2025 | -62.23 Mn |
| Mar 31, 2025 | -48.84 Mn |
| Dec 31, 2024 | -45.24 Mn |
| Sep 30, 2024 | -32.75 Mn |
| Jun 30, 2024 | -34.55 Mn |
| Mar 31, 2024 | -33.32 Mn |
| Dec 31, 2023 | -16.35 Mn |
| Sep 30, 2023 | -14.40 Mn |
| Jun 30, 2023 | -22.76 Mn |
| Mar 31, 2023 | -21.55 Mn |
| Dec 31, 2022 | -43.74 Mn |
| Sep 30, 2022 | -18.40 Mn |
| Jun 30, 2022 | -19.22 Mn |
| Mar 31, 2022 | -18.28 Mn |
| Dec 31, 2021 | -18.05 Mn |
| Sep 30, 2021 | -15.31 Mn |